Neurological Surgery 脳神経外科52巻5号

2024年09月発行

総説

脳血管疾患の遺伝子解析研究

著者： 宮脇哲¹ 本郷博貴¹ 虎澤誠英¹ 小川正太郎¹ 齊藤延人¹

所属機関： ¹東京大学医学部脳神経外科

ページ範囲：P.1057 - P.1081

Ⅰ はじめに
　遺伝子解析技術の進歩に伴い，多くの疾患の遺伝的および分子生物学的な背景が明らかになってきている．脳血管疾患もその研究対象となり，近年多くの発見がなされている．遺伝子解析には，遺伝子変異の解析，遺伝子発現レベルの解析，DNAのメチル化やヒストン修飾などのエピゲノム解析が含まれ，これらの異常が疾患発症に関与している可能性がある．本稿では，近年のさまざまな脳血管疾患の遺伝子解析研究の成果を概説し，特に遺伝子変異レベルの解析に焦点を当てる．

参考文献

1）Ozaki K, et al：Functional SNPs in the lymphotoxin-alpha gene that are associated with susceptibility to myocardial infarction. Nat Genet 32：650-654, 2002

2）Hartiala JA, et al：Genome-wide analysis identifies novel susceptibility loci for myocardial infarction. Eur Heart J 42：919-933, 2021

3）Mahajan A, et al：Multi-ancestry genetic study of type 2 diabetes highlights the power of diverse populations for discovery and translation. Nat Genet 54：560-572, 2022

4）Mishra A, et al：Stroke genetics informs drug discovery and risk prediction across ancestries. Nature 611：115-123, 2022

5）Nikolaev SI, et al：Somatic activating KRAS mutations in arteriovenous malformations of the brain. N Engl J Med 378：250-261, 2018

6）Hong T, et al：High prevalence of KRAS/BRAF somatic mutations in brain and spinal cord arteriovenous malformations. Brain 142：23-34, 2019

7）Peyre M, et al：Somatic PIK3CA mutations in sporadic cerebral cavernous malformations. N Engl J Med 385：996-1004, 2021

8）Hong T, et al：Somatic MAP3K3 and PIK3CA mutations in sporadic cerebral and spinal cord cavernous malformations. Brain 144：2648-2658, 2021

9）Hongo H, et al：Somatic GJA4 gain-of-function mutation in orbital cavernous venous malformations. Angiogenesis 26：37-52, 2023

10）Kuroda S, et al：Moyamoya disease：current concepts and future perspectives. Lancet Neurol 7：1056-1066, 2008

11）Kamada F, et al：A genome-wide association study identifies RNF213 as the first Moyamoya disease gene. J Hum Genet 56：34-40, 2011

12）Liu W, et al：Identification of RNF213 as a susceptibility gene for moyamoya disease and its possible role in vascular development. PLoS One 6：e22542, 2011　doi:10.1371/journal.pone.0022542

13）Miyatake S, et al：Homozygous c.14576G ＞ A variant of RNF213 predicts early-onset and severe form of moyamoya disease. Neurology 78：803-810, 2012

14）Nomura S, et al：Genotype-phenotype correlation in long-term cohort of Japanese patients with moyamoya disease. Cerebrovasc Dis 47：105-111, 2019

15）Wang Y, et al：Validation and extension study exploring the role of RNF213 p.R4810K in 2, 877 Chinese moyamoya disease patients. J Stroke Cerebrovasc Dis 30：106071, 2021　doi:10.1016/j.jstrokecerebrovasdis.2021.106071

16）Wu Z, et al：Molecular analysis of RNF213 gene for moyamoya disease in the Chinese Han population. PLoS One 7：e48179, 2012　doi:10.1371/journal.pone.0048179

17）Ge P, et al：Association between p.R4810K variant and long-term clinical outcome in patients with moyamoya disease. Front Neurol 10：662, 2019　doi:10.3389/fneur.2019.00662

in the phenotype of Chinese moyamoya disease. Neurology 94：e678-e686, 2020　doi:10.1212/WNL.0000000000008901

p.R4810K variant for moyamoya disease. Eur J Neurol 28：823-836, 2021

20）Otten EG, et al：Ubiquitylation of lipopolysaccharide by RNF213 during bacterial infection. Nature 594：111-116, 2021

21）Sugihara M, et al：The AAA＋ ATPase/ubiquitin ligase mysterin stabilizes cytoplasmic lipid droplets. J Cell Biol 218：949-960, 2019

22）Hitomi T, et al：Downregulation of Securin by the variant RNF213 R4810K（rs112735431, G ＞ A）reduces angiogenic activity of induced pluripotent stem cell-derived vascular endothelial cells from moyamoya patients. Biochem Biophys Res Commun 438：13-19, 2013

23）Liu W, et al：Identification of RNF213 as a susceptibility gene for moyamoya disease and its possible role in vascular development. PLoS One 6：e22542, 2011　doi:10.1371/journal.pone.0022542

24）Sonobe S, et al：Temporal profile of the vascular anatomy evaluated by 9.4-T magnetic resonance angiography and histopathological analysis in mice lacking RNF213：a susceptibility gene for moyamoya disease. Brain Res 1552：64-71, 2014

25）Kotani Y, et al：Neuromuscular regulation in zebrafish by a large AAA＋ ATPase/ubiquitin ligase, mysterin/RNF213. Sci Rep 5：16161, 2015　doi:10.1038/srep161612

26）Kobayashi H, et al：Biochemical and functional characterization of RNF213（Mysterin）R4810K, a susceptibility mutation of moyamoya disease, in angiogenesis in vitro and in vivo. J Am Heart Assoc 4：e002146, 2015　doi:10.1161/JAHA.115.002146

27）Correction to Lancet Neurol 2022；published online Sept 29. https://doi.org/10.1016/S1474-4422(22)00309-X. Lancet Neurol 21：e10, 2022　doi:10.1016/S1474-4422(22)00411-2

28）Guey S, et al：Rare RNF213 variants in the C-terminal region encompassing the RING-finger domain are associated with moyamoya angiopathy in Caucasians. Eur J Hum Genet 25：995-1003, 2017

29）Hara S, et al：Absence of the RNF213 p.R4810K variant may indicate a severe form of pediatric moyamoya disease in Japanese patients. J Neurosurg Pediatr 29：48-56, 2022

30）Torazawa S, et al：RNF213 p.Arg4810Lys wild type is associated with de novo hemorrhage in asymptomatic hemispheres with moyamoya disease. Transl Stroke Res, 2023［Epub ahead of print］　doi:10.1007/s12975-023-01159-z

31）Zanoni P, et al：The genetic landscape and clinical implication of pediatric Moyamoya angiopathy in an international cohort. Eur J Hum Genet 31：784-792, 2023

32）Kuroda S, et al；Research Committee on Moyamoya Disease（Spontaneous Occlusion of Circle of Willis）of the Ministry of Health, Labor, and Welfare, Japan：Diagnostic Criteria for Moyamoya Disease - 2021 Revised Version. Neurol Med Chir（Tokyo）62：307-312, 2022

33）Guey S, et al：Moyamoya disease and syndromes：from genetics to clinical management. Appl Clin Genet 8：49, 2015　doi:10.2147/tacg.s42772

34）Koizumi A, et al：A new horizon of moyamoya disease and associated health risks explored through RNF213. Environ Health Prev Med 21：55-70, 2016

variants in non—East Asian patients with sporadic Moyamoya disease. JAMA Neurol 78：993-1003, 2021

36）Pinard A, et al；University of Washington Center for Mendelian Genomics：Rare variants in ANO1, encoding a calcium-activated chloride channel, predispose to moyamoya disease. Brain 146：3616-3623, 2023

37）Guey S, et al：Biallelic variants in NOS3 and GUCY1A3, the two major genes of the nitric oxide pathway, cause moyamoya cerebral angiopathy. Human Genomics 17：24, 2023　doi:10.1186/s40246-023-00471-x

of moyamoya disease. Ann Hum Genet 85：166-177, 2021

39）Banerjee C, Chimowitz MI：Stroke caused by atherosclerosis of the major intracranial arteries. Circ Res 120：502-513, 2017

40）Holmstedt CA, et al：Atherosclerotic intracranial arterial stenosis：risk factors, diagnosis, and treatment. Lancet Neurol 12：1106-1114, 2013

41）Adams HP Jr, et al：Classification of subtype of acute ischemic stroke. Definitions for use in a multicenter clinical trial. TOAST. Trial of Org 10172 in Acute Stroke Treatment. Stroke 24：35-41, 1993

42）White H, et al：Ischemic stroke subtype incidence among whites, blacks, and Hispanics：the Northern Manhattan Study. Circulation 111：1327-1331, 2005

43）Gorelick PB, et al：Large artery intracranial occlusive disease：a large worldwide burden but a relatively neglected frontier. Stroke 39：2396-2399, 2008

44）Suri MFK, et al：Cognitive impairment and intracranial atherosclerotic stenosis in general population. Neurology 90：e1240-e1247, 2018　doi:10.1212/WNL.0000000000005250

45）Liu M, Gutierrez J：Genetic risk factors of intracranial atherosclerosis. Curr Atheroscler Rep 22：13, 2020　doi:10.1007/s11883-020-0831-5

46）Abboud S, et al：Associations of apolipoprotein E gene with ischemic stroke and intracranial atherosclerosis. Eur J Hum Genet 16：955-960, 2008

47）Cui M, et al：Association of ADIPOQ single nucleotide polymorphisms with the risk of intracranial atherosclerosis. Int J Neurosci 127：427-432, 2017

48）Kalita J, et al：Phosphodiesterase 4 D gene polymorphism in relation to intracranial and extracranial atherosclerosis in ischemic stroke. Dis Markers 31：191-197, 2011

49）Liu W, et al：A rare Asian founder polymorphism of Raptor may explain the high prevalence of Moyamoya disease among East Asians and its low prevalence among Caucasians. Environ Health Prev Med 15：94-104, 2010

50）Miyawaki S, et al：Genetic variant RNF213 c.14576G ＞ A in various phenotypes of intracranial major artery stenosis/occlusion. Stroke 44：2894-2897, 2013

51）Miyawaki S, et al：Identification of a genetic variant common to moyamoya disease and intracranial major artery stenosis/occlusion. Stroke 43：3371-3374, 2012

52）Shinya Y, et al：Genetic analysis of ring finger protein 213（RNF213）c.14576G ＞ A in intracranial atherosclerosis of the anterior and posterior circulations. J Stroke Cerebrovasc Dis 26：2638-2644, 2017

53）Bang OY, et al：Adult Moyamoya disease：a burden of intracranial stenosis in East Asians? PLoS One 10：e0130663, 2015 doi:10.1371/journal.pone.0130663

54）Bang OY, et al：A polymorphism in RNF213 is a susceptibility gene for intracranial atherosclerosis. PLoS One 11：e0156607, 2016　doi:10.1371/journal.pone.0156607

55）Kim YJ, et al：Nonatheroscleotic isolated middle cerebral artery disease may be early manifestation of moyamoya disease. Stroke 47：2229-2235, 2016

56）Park MG, et al：RNF213 rs112735431 polymorphism in intracranial artery steno-occlusive disease and moyamoya disease in Koreans. J Neurol Sci 375：331-334, 2017

57）Kim YJ, et al：Are genetic variants associated with the location of cerebral arterial lesions in stroke patients? Cerebrovasc Dis 49：262-268, 2020

58）Kim J, et al：Distribution of intracranial major artery stenosis/occlusion according to RNF213 polymorphisms. Int J Mol Sci 21：1956, 2020　doi:10.3390/ijms21061956

59）Zhang T, et al：Genetic analysis of RNF213 p.R4810K variant in non-moyamoya intracranial artery stenosis/occlusion disease in a Chinese population. Environ Health Prev Med 22：41, 2017　doi:10.1186/s12199-017-0649-0

60）Xue S, et al：The association between the ring finger protein 213 gene R4810K variant and intracranial major artery stenosis/occlusion in the Han Chinese population and high-resolution magnetic resonance imaging findings. Brain Circ 4：33-39, 2018

61）Zhang Q, et al：Association of ring finger protein 213 gene P.R4810k polymorphism with intracranial major artery stenosis/occlusion. J Stroke Cerebrovasc Dis 27：1556-1564, 2018

62）Sun X, et al：Prevalence of RNF213 variants in symptomatic intracranial arterial stenosis/occlusion in China. Mol Genet Genomics 295：635-643, 2020

63）Liao X, et al：Rare variants of RNF213 and moyamoya/non-moyamoya intracranial artery stenosis/occlusion disease risk：a meta-analysis and systematic review. Environ Health Prev Med 22：75, 2017　doi:10.1186/s12199-017-0680-1

64）Cao Y, et al：Frequency of RNF213 p.R4810K, a susceptibility variant for moyamoya disease, and health characteristics of carriers in the Japanese population. Environ Health Prev Med 21：387-390, 2016

65）Hongo H, et al：Comprehensive investigation of RNF213 nonsynonymous variants associated with intracranial artery stenosis. Sci Rep 10：11942, 2020　doi:10.1038/s41598-020-68888-1

66）National Library of Medicine.　https://www.ncbi.nlm.nih.gov/snp/（2024年5月10日アクセス）

67）Dofuku S, et al：Genome-wide association study of intracranial artery stenosis followed by phenome-wide association study. Transl Stroke Res 14：322-333, 2023

68）Kubo M, et al：A nonsynonymous SNP in PRKCH（protein kinase C eta）increases the risk of cerebral infarction. Nat Genet 39：212-217, 2007

69）Traylor M, et al：Genetic risk factors for ischaemic stroke and its subtypes（the METASTROKE collaboration）：a meta-analysis of genome-wide association studies. Lancet Neurol 11：951-962 2012

70）Malik R, et al：Multiancestry genome-wide association study of 520, 000 subjects identifies 32 loci associated with stroke and stroke subtypes. Nat Genet 50：524-537, 2018

71）Okazaki S, et al：Moyamoya disease susceptibility variant RNF213 p.R4810K increases the risk of ischemic stroke attributable to large-artery atherosclerosis. Circulation 139：295-298, 2019

72）Tabara Y, et al：The association between the Moyamoya disease susceptible gene RNF213 variant and incident cardiovascular disease in a general population：the Nagahama study. J Hypertens 39：2521-2526, 2021

73）Koizumi A, et al：P.R4810K, a polymorphism of RNF213, the susceptibility gene for moyamoya disease, is associated with blood pressure. Environ Health Prev Med 18：121-129, 2013

74）Morimoto T, et al：Significant association of RNF213 p.R4810K, a moyamoya susceptibility variant, with coronary artery disease. PLoS One 12：e0175649, 2017　doi:10.1371/journal.pone.0175649

75）Hiraide T, et al：Poor outcomes in carriers of the RNF213 variant（p.Arg4810Lys）with pulmonary arterial hypertension. J Heart Lung Transplant 39：103-112, 2020

76）Gamou S, et al：Genetics in pulmonary arterial hypertension in a large homogeneous Japanese population. Clin Genet 94：70-80, 2018

77）Chang SA, et al：Nonsyndromic peripheral pulmonary artery stenosis is associated with homozygosity of RNF213 p.Arg4810Lys regardless of co-occurrence of Moyamoya disease. Chest 153：404-413, 2018

78）Hara S, et al：De novo renal artery stenosis developed in initially normal renal arteries during the long-term follow-up of patients with moyamoya disease. J Stroke Cerebrovasc Dis 29：104786, 2020　doi:10.1016/j.jstrokecerebrovasdis.2020.104786

79）Baek JW, et al：Prevalence and clinical implications of renal artery stenosis in pediatric moyamoya disease. Eur J Paediatr Neurol 20：20-24, 2016

80）Bakker MK, et al：Genome-wide association study of intracranial aneurysms identifies 17 risk loci and genetic overlap with clinical risk factors. Nat Genet 52：1303-1313, 2020

81）Karasozen Y, et al：Somatic PDGFRB activating variants in fusiform cerebral aneurysms. Am J Hum Genet 104：968-976, 2019

82）Shima Y, et al：Increased PDGFRB and NF-κB signaling caused by highly prevalent somatic mutations in intracranial aneurysms. Sci Transl Med 15：eabq7721, 2023　doi:10.1126/scitranslmed.abq7721

83）Winkler EA, et al：A single-cell atlas of the normal and malformed human brain vasculature. Science 375：eabi7377, 2022　doi:10.1126/science.abi7377

84）Robinson JR, et al：Natural history of the cavernous angioma. J Neurosurg 75：709-714, 1991

85）Al-Holou WN, et al：Natural history and imaging prevalence of cavernous malformations in children and young adults. J Neurosurg Pediatr 9：198-205, 2012

86）Maddaluno L, et al：EndMT contributes to the onset and progression of cerebral cavernous malformations. Nature 498：492-496, 2013

87）Zhou Z, et al：Cerebral cavernous malformations arise from endothelial gain of MEKK3-KLF2/4 signalling. Nature 532：122-126, 2016

88）Ren AA, et al：PIK3CA and CCM mutations fuel cavernomas through a cancer-like mechanism. Nature 594：271-276, 2021

89）Geraldo AF, et al：Natural history of familial cerebral cavernous malformation syndrome in children：a multicenter cohort study. Neuroradiology 65：401-414, 2023

90）Laberge-le Couteulx S, et al：Truncating mutations in CCM1, encoding KRIT1, cause hereditary cavernous angiomas. Nat Genet 23：189-193, 1999

91）Sahoo T, et al：Mutations in the gene encoding KRIT1, a Krev-1/rap1a binding protein, cause cerebral cavernous malformations（CCM1）. Hum Mol Genet 8：2325-2333, 1999

92）Liquori CL, et al：Mutations in a gene encoding a novel protein containing a phosphotyrosine-binding domain cause type 2 cerebral cavernous malformations. Am J Hum Genet 73：1459-1464, 2003

93）Denier C, et al：Mutations within the MGC4607 gene cause cerebral cavernous malformations. Am J Hum Genet 74：326-337, 2004

94）Bergametti F, et al：Mutations within the programmed cell death 10 gene cause cerebral cavernous malformations. Am J Hum Genet 76：42-51, 2005

95）Denier C, et al：Genotype-phenotype correlations in cerebral cavernous malformations patients. Ann Neurol 60：550-556, 2006

96）Stahl S, et al：Novel CCM1, CCM2, and CCM3 mutations in patients with cerebral cavernous malformations：in-frame deletion in CCM2 prevents formation of a CCM1/CCM2/CCM3 protein complex. Hum Mutat 29：709-717, 2008

97）Padarti A, et al：Recent advances in cerebral cavernous malformation research. Vessel Plus 2：21, 2018　doi:10.20517/2574-1209.2018.34

98）Abou-Fadel J, et al：CCM signaling complex（CSC）couples both classic and non-classic Progesterone receptor signaling. Cell Commun Signal 20：120, 2022　doi:10.1186/s12964-022-00926-z

99）Akers AL, et al：Biallelic somatic and germline mutations in cerebral cavernous malformations（CCMs）：evidence for a two-hit mechanism of CCM pathogenesis. Hum Mol Genet 18：919-930, 2009

100）Knudson AG Jr：Mutation and cancer：statistical study of retinoblastoma. Proc Natl Acad Sci U S A 68：820-823, 1971

101）Ren J, et al：Somatic variants of MAP3K3 are sufficient to cause cerebral and spinal cord cavernous malformations. Brain 146：3634-3647, 2023

102）Weng J, et al：Somatic MAP3K3 mutation defines a subclass of cerebral cavernous malformation. Am J Hum Genet 108：942-950, 2021

103）Snellings DA, et al：Developmental venous anomalies are a genetic primer for cerebral cavernous malformations. Nat Cardiovasc Res 1：246-252, 2022

104）Riant F, et al：CCM3 mutations are associated with early-onset cerebral hemorrhage and multiple meningiomas. Mol Syndromol 4：165-172, 2013

105）Fox CK, et al：Seizure incidence rates in children and adults with familial cerebral cavernous malformations. Neurology 97：e1210-e1216, 2021　doi:10.1212/WNL.0000000000012569

106）Robinson JR Jr, et al：Factors predisposing to clinical disability in patients with cavernous malformations of the brain. Neurosurgery 32：730-736, 1993

107）Zabramski JM, et al：The natural history of familial cavernous malformations：results of an ongoing study. J Neurosurg 80：422-432, 1994

108）Jeon JS, et al：A risk factor analysis of prospective symptomatic haemorrhage in adult patients with cerebral cavernous malformation. J Neurol Neurosurg Psychiatry 85：1366-1370, 2014

109）Labauge P, et al：Genetics of cavernous angiomas. Lancet Neurol 6：237-244, 2007

110）Clatterbuck RE, et al：The nature and fate of punctate（type IV）cavernous malformations. Neurosurgery 49：26-32, 2001

111）Gross BA, et al：The natural history of cerebral cavernous malformations in children. J Neurosurg Pediatr 17：123-128, 2016

112）Dammann P, et al：Correlation of the venous angioarchitecture of multiple cerebral cavernous malformations with familial or sporadic disease：a susceptibility-weighted imaging study with 7-Tesla MRI. J Neurosurg 126：570-577, 2017

113）He Y, et al：Stabilization of VEGFR2 signaling by cerebral cavernous malformation 3 is critical for vascular development. Sci Signal 3：ra26, 2010　doi:10.1126/scisignal.2000722

114）Whitehead KJ, et al：Ccm1 is required for arterial morphogenesis：implications for the etiology of human cavernous malformations. Development 131：1437-1448, 2004

115）Whitehead KJ, et al：The cerebral cavernous malformation signaling pathway promotes vascular integrity via Rho GTPases. Nat Med 15：177-184, 2009

116）Boulday G, et al：Tissue-specific conditional CCM2 knockout mice establish the essential role of endothelial CCM2 in angiogenesis：implications for human cerebral cavernous malformations. Dis Model Mech 2：168-177, 2009

117）Cunningham K, et al：Conditional deletion of Ccm2 causes hemorrhage in the adult brain：a mouse model of human cerebral cavernous malformations. Hum Mol Genet 20：3198-3206, 2011

118）Phillips CM, et al：Cerebral cavernous malformation pathogenesis：investigating lesion formation and progression with animal models. Int J Mol Sci 23：5000, 2022　doi:10.3390/ijms23095000

119）Shenkar R, et al：Rho kinase inhibition blunts lesion development and hemorrhage in murine models of aggressive Pdcd10/Ccm3 disease. Stroke 50：738-744, 2019

120）Polster SP, et al：Atorvastatin treatment of cavernous angiomas with symptomatic hemorrhage exploratory proof of concept（AT CASH EPOC）trial. Neurosurgery 85：843-853, 2019

121）McDonald DA, et al：Fasudil decreases lesion burden in a murine model of cerebral cavernous malformation disease. Stroke 43：571-574, 2012

122）Shenkar R, et al：RhoA kinase inhibition with Fasudil versus simvastatin in murine models of cerebral cavernous malformations. Stroke 48：187-194, 2017

123）Léauté-Labrèze C, et al：A randomized, controlled trial of oral propranolol in infantile hemangioma. N Engl J Med 372：735-746, 2015

124）Zabramski JM, et al：Propranolol treatment of cavernous malformations with symptomatic hemorrhage. World Neurosurg 88：631-639, 2016

125）Li W, et al：Propranolol inhibits cavernous vascular malformations by β1 adrenergic receptor antagonism in animal models. J Clin Invest 131：e144893, 2021　doi:10.1172/JCI144893

126）de Paiva BBM, et al：Potential and limitations of machine meta-learning（ensemble）methods for predicting COVID-19 mortality in a large inhospital Brazilian dataset. Sci Rep 13：3463, 2023　doi:10.1038/s41598-023-28579-z

127）Lanfranconi S, et al：Safety and efficacy of propranolol for treatment of familial cerebral cavernous malformations（Treat_CCM）：a randomised, open-label, blinded-endpoint, phase 2 pilot trial. Lancet Neurol 22：35-44, 2023

128）Gibson CC, et al：Strategy for identifying repurposed drugs for the treatment of cerebral cavernous malformation. Circulation 131：289-299, 2015

129）Bravi L, et al：Sulindac metabolites decrease cerebrovascular malformations in CCM3-knockout mice. Proc Natl Acad Sci U S A 112：8421-8426, 2015

130）Choi JP, et al：Ponatinib（AP24534）inhibits MEKK3-KLF signaling and prevents formation and progression of cerebral cavernous malformations. Sci Adv 4：eaau0731, 2018　doi:10.1126/sciadv.aau0731

131）Brinjikji W, et al：Prevalence and characteristics of brain arteriovenous malformations in hereditary hemorrhagic telangiectasia：a systematic review and meta-analysis. J Neurosurg 127：302-310, 2017

132）McAllister KA, et al：Endoglin, a TGF-β binding protein of endothelial cells, is the gene for hereditary haemorrhagic telangiectasia type 1. Nat Genet 8：345-351, 1994

133）Johnson DW, et al：Mutations in the activin receptor—like kinase 1 gene in hereditary haemorrhagic telangiectasia type 2. Nat Genet 13：189-195, 1996

134）Gallione CJ, et al：A combined syndrome of juvenile polyposis and hereditary haemorrhagic telangiectasia associated with mutations in MADH4（SMAD4）. Lancet 363：852-859, 2004

135）Richards-Yutz J, et al：Update on molecular diagnosis of hereditary hemorrhagic telangiectasia. Hum Genet 128：61-77, 2010

136）Bernabeu C, et al：Potential second-hits in hereditary hemorrhagic telangiectasia. J Clin Med 9：3571, 2020　doi:10.3390/jcm9113571

137）Gallione CJ, et al：SMAD4 mutations found in unselected HHT patients. J Med Genet 43：793-797, 2006

138）Valdivielso-Ramos M, et al：Capillary malformation-arteriovenous malformation syndrome：a multicentre study. Clin Exp Dermatol 46：300-305, 2021

139）Revencu N, et al：RASA1 mutations and associated phenotypes in 68 families with capillary malformation-arteriovenous malformation. Hum Mutat 34：1632-1641, 2013

140）Amyere M, et al：Germline loss-of-function mutations in EPHB4 cause a second form of capillary malformation-arteriovenous malformation（CM-AVM2）deregulating RAS-MAPK signaling. Circulation 136：1037-1048, 2017

141）Weinsheimer S, et al：Genome-wide association study of sporadic brain arteriovenous malformations. J Neurol Neurosurg Psychiatry 87：916-923, 2016

142）Pawlikowska L, et al：Polymorphisms in transforming growth factor-β-related genes ALK1 and ENG are associated with sporadic brain arteriovenous malformations. Stroke 36：2278-2280, 2005

143）Kim H, et al：Population stratification in a case-control study of brain arteriovenous malformation in Latinos. Neuroepidemiology 31：224-228, 2008

144）Kim H, et al：Common variants in interleukin-1-Beta gene are associated with intracranial hemorrhage and susceptibility to brain arteriovenous malformation. Cerebrovasc Dis 27：176-182, 2009

145）Zhao Y, et al：The rs522616 polymorphism in the matrix metalloproteinase-3（MMP-3）gene is associated with sporadic brain arteriovenous malformation in a Chinese population. J Clin Neurosci 17：1568-1572, 2010

146）Chen H, et al：Polymorphisms of the vascular endothelial growth factor A gene and susceptibility to sporadic brain arteriovenous malformation in a Chinese population. J Clin Neurosci 18：549-553, 2011

147）Jiang N, et al：Susceptible gene single nucleotide polymorphism and hemorrhage risk in patients with brain arteriovenous malformation. J Clin Neurosci 18：1279-1281, 2011

148）Mikhak B, et al：Angiopoietin-like 4（ANGPTL4）gene polymorphisms and risk of brain arteriovenous malformations. Cerebrovasc Dis 31：338-345, 2011

149）Fontanella M, et al：Brain arteriovenous malformations are associated with interleukin-1 cluster gene polymorphisms. Neurosurgery 70：12-17, 2012

150）Erkinova SA, et al：Angiopoietin-like proteins 4（ANGPTL4）gene polymorphisms and risk of brain arteriovenous malformation. J Stroke Cerebrovasc Dis 27：908-913, 2018

151）Li H, et al：De novo germline and somatic variants convergently promote endothelial-to-mesenchymal transition in simplex brain arteriovenous malformation. Circ Res 129：825-839, 2021

152）Snellings DA, et al：Somatic mutations in vascular malformations of hereditary hemorrhagic telangiectasia result in bi-allelic loss of ENG or ACVRL1. Am J Hum Genet 105：894-906, 2019

153）Macmurdo CF, et al：RASA1 somatic mutation and variable expressivity in capillary malformation/arteriovenous malformation（CM/AVM）syndrome. Am J Med Genet A 170：1450-1454, 2016

154）Lapinski PE, et al：Somatic second hit mutation of RASA1 in vascular endothelial cells in capillary malformation-arteriovenous malformation. Eur J Med Genet 61：11-16, 2018

155）Nikolaev SI, et al：Somatic activating KRAS mutations in arteriovenous malformations of the brain. N Engl J Med 378：250-261, 2018

156）Hong T, et al：High prevalence of KRAS/BRAF somatic mutations in brain and spinal cord arteriovenous malformations. Brain 142：23-34, 2019

157）Priemer DS, et al：Activating KRAS mutations in arteriovenous malformations of the brain：frequency and clinicopathologic correlation. Hum Pathol 89：33-39, 2019

158）Goss JA, et al：Somatic mutations in intracranial arteriovenous malformations. PLoS One 14：e0226852, 2019　doi:10.1371/journal.pone.0226852

159）Oka M, et al：KRAS G12D or G12V mutation in human brain arteriovenous malformations. World Neurosurg 126：e1365-e1373, 2019　doi:10.1016/j.wneu.2019.03.105

160）Bameri O, et al：KRAS/BRAF mutations in brain arteriovenous malformations：a systematic review and meta-analysis. Interv Neuroradiol 27：539-546, 2021

161）Bayrak-Toydemir P, et al：Genotype-phenotype correlation in hereditary hemorrhagic telangiectasia：mutations and manifestations. Am J Med Genet A 140：463-470, 2006

162）Rossi E, et al：Endoglin as an adhesion molecule in mature and progenitor endothelial cells：a function beyond TGF-β. Front Med（Lausanne）6：10, 2019　doi:10.3389/fmed.2019.00010

163）McDonald J, et al：Hereditary hemorrhagic telangiectasia：genetics and molecular diagnostics in a new era. Front Genet 6：1, 2015　doi:10.3389/fgene.2015.00001

164）Abdalla SA, et al：Hereditary haemorrhagic telangiectasia：current views on genetics and mechanisms of disease. J Med Genet 43：97-110, 2006

165）Bourdeau A, et al：Endoglin-deficient mice, a unique model to study hereditary hemorrhagic telangiectasia. Trends Cardiovasc Med 10：279-285, 2000

166）Tual-Chalot S, et al：Mouse models of hereditary hemorrhagic telangiectasia：recent advances and future challenges. Front Genet 6：25, 2015　doi:10.3389/fgene.2015.00025

167）Ruiz-Llorente L, et al：Endoglin and alk1 as therapeutic targets for hereditary hemorrhagic telangiectasia. Expert Opin Ther Targets 21：933-947, 2017

168）Urness LD, et al：Arteriovenous malformations in mice lacking activin receptor-like kinase-1. Nat Genet 26：328-331, 2000

169）Li DY, et al：Defective angiogenesis in mice lacking endoglin. Science 284：1534-1537, 1999

170）Ola R, et al：SMAD4 prevents flow induced arteriovenous malformations by inhibiting casein kinase 2. Circulation 138：2379-2394, 2018

171）Gil M, et al：Hydroids（Cnidaria, Hydrozoa）from Mauritanian coral mounds. Zootaxa 4878：zootaxa.4878.3.2, 2020　doi:10.11646/zootaxa.4878.3.2

172）Gasper R, et al：The Ras switch in structural and historical perspective. Biol Chem 401：143-163, 2019

173）Bai J, et al：Ephrin B2 and EphB4 selectively mark arterial and venous vessels in cerebral arteriovenous malformation. J Int Med Res 42：405-415, 2014

174）Henkemeyer M, et al：Vascular system defects and neuronal apoptosis in mice lacking ras GTPase-activating protein. Nature 377：695-701, 1995

175）Gerety SS, et al：Symmetrical mutant phenotypes of the receptor EphB4 and its specific transmembrane ligand ephrin-B2 in cardiovascular development. Mol Cell 4：403-414, 1999

176）Simanshu DK, et al：RAS proteins and their regulators in human disease. Cell 170：17-33, 2017

177）Meadows KN, et al：Vascular endothelial growth factor induction of the angiogenic phenotype requires Ras activation. J Biol Chem 276：49289-49298, 2001

178）Fish JE, et al：Somatic gain of KRAS function in the endothelium is sufficient to cause vascular malformations that require MEK but not PI3K signaling. Circ Res 127：727-743, 2020

179）Park ES, et al：Selective endothelial hyperactivation of oncogenic KRAS induces brain arteriovenous malformations in mice. Ann Neurol 89：926-941, 2021